Free Trial
NASDAQ:PHAT

Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

Phathom Pharmaceuticals logo
$9.63 +0.58 (+6.41%)
Closing price 04:00 PM Eastern
Extended Trading
$9.51 -0.12 (-1.24%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)

Key Stats

Today's Range
$8.83
$9.71
50-Day Range
$3.90
$10.90
52-Week Range
$2.21
$19.71
Volume
1.67 million shs
Average Volume
977,777 shs
Market Capitalization
$672.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50
Consensus Rating
Buy

Company Overview

Phathom Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

PHAT MarketRank™: 

Phathom Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 136th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Phathom Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Phathom Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Phathom Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.78) to ($4.02) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Phathom Pharmaceuticals is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Phathom Pharmaceuticals is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Phathom Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    15.85% of the float of Phathom Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Phathom Pharmaceuticals has recently decreased by 22.83%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Phathom Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Phathom Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.85% of the float of Phathom Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Phathom Pharmaceuticals has recently decreased by 22.83%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Phathom Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Phathom Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    10 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Phathom Pharmaceuticals insiders have bought 95.06% more of their company's stock than they have sold. Specifically, they have bought $27,591.00 in company stock and sold $14,145.00 in company stock.

  • Percentage Held by Insiders

    23.00% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Phathom Pharmaceuticals' insider trading history.
Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAT Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Phathom Pharmaceuticals, Inc. (PHAT) - Yahoo Finance
See More Headlines

PHAT Stock Analysis - Frequently Asked Questions

Phathom Pharmaceuticals' stock was trading at $8.12 at the start of the year. Since then, PHAT stock has increased by 18.6% and is now trading at $9.63.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its earnings results on Thursday, November, 7th. The company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.57) by $0.25. The company earned $16.35 million during the quarter, compared to analyst estimates of $12.54 million.
Read the conference call transcript
.

Phathom Pharmaceuticals (PHAT) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager.

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), Waste Connections (WCN), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
11/07/2024
Today
7/25/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHAT
CIK
1783183
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$28.00
Low Price Target
$5.00
Potential Upside/Downside
+81.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$334.33 million
Net Margins
-422.42%
Pretax Margin
-422.42%
Return on Equity
N/A
Return on Assets
-90.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.58
Quick Ratio
3.54

Sales & Book Value

Annual Sales
$55.25 million
Price / Sales
12.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.71) per share
Price / Book
-2.60

Miscellaneous

Outstanding Shares
69,810,000
Free Float
53,757,000
Market Cap
$672.27 million
Optionable
Optionable
Beta
0.45
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:PHAT) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners